License Agreement Sample Contracts

Newmarkt Corp. – Intellectual Property Portfolio License Agreement (August 20th, 2018)

This agreement, dated as of February 1,2018 (the "Effective date") is by and between Loubert S. Suddaby, MD ("Licensor") and Spinus, LLC (hereinafter referred to as the " Company"), collectively hereinafter referred to as the "Parties" and each hereinafter referred to a "Party").

Principia Biopharma Inc. – License Agreement (August 17th, 2018)

THIS LICENSE AGREEMENT (the Agreement) is entered into as of November 8, 2017 (the Signing Date) by and between, on the one hand, PRINCIPIA BIOPHARMA, INC., a Delaware corporation having its principal place of business at 400 East Jamie Court, Suite 302, South San Francisco, California 94080 (Principia), and, on the other hand, Genzyme Corporation, a Massachusetts corporation having its principal place of business at 500 Kendall Street, Cambridge, Massachusetts 02142 (Sanofi). Principia and Sanofi are sometimes referred to herein individually as a Party and collectively as the Parties.

Prothena Corporation Plc – License Agreement Amendment Number One (August 17th, 2018)
Prothena Corporation Plc – License Agreement Between Neotope Biosciences Limited and the Regents of the University of California for Case No. Sd2002-035 (August 17th, 2018)
Carter Validus Mission Critical REIT, Inc. – Lease Termination and License Agreement (August 16th, 2018)

THIS LEASE TERMINATION AND LICENSE AGREEMENT (this "Agreement") is made and entered into effective as of August 13, 2018 (the "Effective Date"), by and between HC-200 BLOSSOM STREET, LLC, a Delaware limited liability company ("Landlord"), and BAY AREA REGIONAL MEDICAL CENTER, LLC, a Texas limited liability company ("Tenant").

Amended and Restated Collaborative Research, Development, Commercialization and License Agreement Between Senomyx, Inc. And Firmenich Sa (August 15th, 2018)

THIS AMENDED AND RESTATED AGREEMENT is entered into as of February 7, 2018, by and between SENOMYX, INC., a Delaware Corporation having offices at 4767 Nexus Centre Drive, San Diego, CA 92121, U.S.A. ("Senomyx") and FIRMENICH SA, a Swiss Company, having its principal place of business at 1, route des Jeunes, 1211 Geneva 8, Switzerland ("Firmenich").

Principia Biopharma Inc. – License Agreement (August 15th, 2018)

THIS LICENSE AGREEMENT (the Agreement) is entered into as of November 8, 2017 (the Signing Date) by and between, on the one hand, PRINCIPIA BIOPHARMA, INC., a Delaware corporation having its principal place of business at 400 East Jamie Court, Suite 302, South San Francisco, California 94080 (Principia), and, on the other hand, Genzyme Corporation, a Massachusetts corporation having its principal place of business at 500 Kendall Street, Cambridge, Massachusetts 02142 (Sanofi). Principia and Sanofi are sometimes referred to herein individually as a Party and collectively as the Parties.

License Agreement (August 10th, 2018)

This License Agreement ("Agreement") is entered into as of August 6, 2018 ("Effective Date") between Cleveland BioLabs, Inc., a Delaware corporation ("CBLI") and Genome Protection, Inc., a Delaware corporation ("GPI").

Owl Rock Technology Finance Corp. – License Agreement (August 10th, 2018)

This LICENSE AGREEMENT (this Agreement) is made and effective as of August 10, 2018 (the Effective Date) by and between Owl Rock Capital Partners LP (the Licensor), a Delaware limited partnership, and Owl Rock Technology Finance Corp., a Maryland corporation (the Licensee) (each a party, and collectively, the parties).

Celladon Corp – Amendment #6 to License Agreement (August 10th, 2018)

This Amendment #6 to License Agreement ("Amendment #6") is entered into as of the date of last signature below ("Amendment #6 Effective Date") by and between Merck Sharp & Dohme Corp. (formerly known as Schering Corporation), a New Jersey corporation having a place of business at 2000 Galloping Hill Road, Kenilworth, NJ 07033 ("Merck") and Eiger BioPharmaceuticals, Inc., a Delaware corporation having a place of business at 350 Cambridge Avenue, Suite 350, Palo Alto, CA 94306 ("Licensee") (each of Merck and Licensee, a "Party", and together, the "Parties") to amend that certain License Agreement between the Parties dated September 3, 2010, as amended on January 18, 2011 and subsequently first amended June 11, 2013, as second amended November 20, 2014, as third amended March 6, 2015, as fourth amended June 9, 2015, and as fifth amended December 15, 2015 (collectively, the "Agreement").

Smart Energy Solutions Inc – License Agreement With Yissum (August 9th, 2018)
Tocagen Inc – License Agreement (August 9th, 2018)

This LICENSE AGREEMENT (this "Agreement"), is entered into as of April 17, 2018 (the "Execution Date"), by and between Tocagen Inc., a Delaware corporation having a principal place of business at 3030 Bunker Hill Street #230, San Diego, California 92109, USA ("Tocagen"); Beijing Apollo Venus Biomedical Technology Limited (Bei Jing A Bo Luo Jin Xing Sheng Wu Yi Yao Ke Ji You Xian Gong Si ), a People's Republic of China company having a principal place of business at B5318, Building 3, No8 Hangfeng Road, Fengtai, Beijing ("Apollo"); and solely for purposes of Sections 13.1 and 13.6, ApolloBio Corp., a People's Republic of China corporation having a principal place of business at Room 277, Building 1, No8 Hangfeng Road, Fengtai, Beijing ("ApolloBio").

INTELLECTUAL PROPERTY RIGHTS CROSS-LICENSE AGREEMENT BY AND BETWEEN NETGEAR, INC. AND ARLO TECHNOLOGIES, INC. Dated as of August 2, 2018 (August 7th, 2018)
Cara Therapeutics – License Agreement (August 7th, 2018)

This License Agreement (the "Agreement") is entered into as of May 17, 2018 (the "Effective Date"), by and between Cara Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having an office located at offices at 4 Stamford Plaza,107 Elm Street, 9th Floor Stamford, CT 06902 ("Cara"), and Vifor Fresenius Medical Care Renal Pharma Ltd., a corporation organized and existing under the laws of Switzerland and having an office located at Rechenstrasse 37, CH-9014 St. Gallen, Switzerland ("VFMCRP").

Arlo Technologies, Inc. – INTELLECTUAL PROPERTY RIGHTS CROSS-LICENSE AGREEMENT BY AND BETWEEN NETGEAR, INC. AND ARLO TECHNOLOGIES, INC. Dated as of August 2, 2018 (August 7th, 2018)
Karyopharm Therapeutics Inc. – Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omission. LICENSE AGREEMENT by and Between KARYOPHARM THERAPEUTICS INC. And ANTENGENE THERAPEUTICS LIMITED (August 7th, 2018)

THIS LICENSE AGREEMENT (this Agreement), effective as of May 23, 2018 (the Effective Date), is made and entered into by and between Karyopharm Therapeutics Inc., a corporation organized and existing under the laws of the State of Delaware, having an address at 85 Wells Avenue, Suite 210, Newton, MA 02459 USA (Karyopharm), and Antengene Therapeutics Limited, a corporation organized and existing under the laws of Hong Kong, having an address at Rm. 19C, Lockhart Ctr., 301-307 Lockhart Rd., Wan Chai, Hong Kong (Antengene). Karyopharm and Antengene are sometimes referred to herein individually as a Party and collectively as the Parties.

Seriesone, Inc – Contribution and License Agreement (August 6th, 2018)

This CONTRIBUTION AND LICENSE AGREEMENT (this Agreement) is entered into as of August 11, 2017 (the Effective Date), by and between Funding Wonder, Inc., a Delaware corporation (FW) and Finfora Inc., a Delaware corporation (Finfora and, together with FW, the Parties).

Versartis, Inc. – License Agreement (August 3rd, 2018)
vTv Therapeutics Inc. – License Agreement (August 3rd, 2018)

THIS LICENSE AGREEMENT is entered into this 31st day of May 2018 (the "Effective Date"), by and between Newsoara Biopharma Co., Ltd., a company organized under the laws of China, having a business address at Room 302-22, Building No. 1, 800 Na Xian Road, Shanghai Free Trade Zone, China ("Newsoara"), and vTv Therapeutics LLC, a limited liability company organized under the laws of Delaware, having a business address at 4170 Mendenhall Oaks Parkway, High Point, NC 27265 ("vTv").

Agios Pharmaceuticals Inc. – Securities and Exchange Commission. Double Asterisks Denote Omissions. LICENSE AGREEMENT BY AND BETWEEN AGIOS PHARMACEUTICALS, INC. AND CSTONE PHARMACEUTICALS (August 2nd, 2018)
License Agreement (August 1st, 2018)

This License Agreement (this "Agreement") is made as of April 16, 2018 (the "Effective Date") by and between (1) ARQULE, INC., a corporation incorporated under the laws of the State of Delaware, US, with its principal place of business at One Wall Street, Burlington, MA 01803, US ("ArQule"); and (2) BASILEA PHARMACEUTICA INTERNATIONAL LIMITED, a corporation incorporated under the laws of Switzerland, with its principal place of business at Grenzacherstrasse 487, 4058 Basel, Switzerland ("Basilea"). ArQule and Basilea are each sometimes referred to herein individually as a "Party" and collectively as the "Parties".

2018 Amendment to November 17, 2005 License Agreement for Wireless Communications Access System Between City of Chicago and Chicago Concourse Development Group, LLC (July 20th, 2018)

This 2018 Amendment to November 17, 2005 License Agreement for Wireless Communications Access System between City of Chicago and Chicago Concourse Development Group, LLC (2018 Amendment) is made as of March 31, 2018 by and between the CITY OF CHICAGO, an Illinois municipal corporation, (the City) and CHICAGO CONCOURSE DEVELOPMENT GROUP, LLC, a subsidiary of BOINGO WIRELESS, INC. (subsidiary and parent company hereby collectively referred to as Boingo).

AgeX Therapeutics, Inc. – License Agreement (July 19th, 2018)

This License Agreement ("Agreement") is made and entered into as of August 17, 2017 (the "Effective Date"), by and between ES Cell International Pte Ltd., a corporation wholly owned by BioTime, Inc. ("BioTime") and duly established under the laws of Singapore, having its registered office at 1010 Atlantic Avenue, Alameda, CA 94501 ("ESI"), and AgeX Therapeutics, Inc., a Delaware corporation ("AgeX"). ESI and AgeX are sometimes hereinafter referred to individually as a "Party" and collectively as the "Parties".

AgeX Therapeutics, Inc. – License Agreement (July 19th, 2018)

THIS LICENSE Agreement ("Agreement") is entered into this 17th day of August, 2017 (the "Effective Date") by and between BIOTIME, INC., a California corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 ("BioTime"), and AGEX THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 ("AgeX").

Aridis Pharmaceuticals, Inc. – License Agreement (July 18th, 2018)

This License Agreement (the Agreement) is made and entered into effective as of January 6, 2010 (the Effective Date), by and between Aridis Pharmaceuticals, LLC a corporation organized and existing under the laws of California (hereinafter Aridis) and Emergent Product Development Gaithersburg Inc., a Delaware corporation (hereinafter Emergent). Aridis and Emergent each may be referred to herein individually as a Party, or collectively as the Parties.

Aridis Pharmaceuticals, Inc. – License Agreement (July 18th, 2018)

This Agreement is made and entered into by and between the University of Iowa Research Foundation (hereinafter UIRF) having offices at 2660 University Capitol Centre, Iowa City, Iowa 52242 and Aridis Pharmaceuticals, LLC (hereinafter Licensee), having offices at 5941 Optical Court, San Jose, CA 95138

World Media & Technology Corp. – Platform License Agreement (July 13th, 2018)

This PLATFORM LICENSE AGREEMENT (this "Agreement") is made and entered into as of October 1, 2017 (the "License Effective Date"), between World Global Network Pte. Ltd., a limited private company incorporated in Singapore, (the "Licensor"), and World Media & Technology Corp., a Nevada corporation (the "Licensee," and together with the Licensor, the "Parties" and each a "Party"). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in that certain Stock Exchange, Debt Forgiveness and Intellectual Property Assignment Agreement between Licensor and Licensee, dated simultaneously herewith (the "SEDFIP Agreement").

Urovant Sciences Ltd. – License Agreement (July 13th, 2018)

THIS LICENSE AGREEMENT (this Agreement) is made and entered into this February 3, 2017 (the Effective Date), by and between Merck Sharp & Dohme Corp. a corporation organized and existing under the laws of the State of New Jersey (Merck), and Urovant Sciences GmbH (Urovant), a company organized and existing pursuant to the laws of Switzerland, [***]. Merck and Urovant are sometimes referred to herein individually as a Party and collectively as the Parties.

Cardiome Pharma Corporation – License Agreement (July 12th, 2018)

This License Agreement (this "Agreement"), effective as of May 5, 2016 (the "Effective Date"), is made by and between Durata Therapeutics International B.V., a private limited company registered in the Netherlands with offices at Barbara Strozzilaan 101, Spaces Zuida, Amsterdam, the Netherlands ("Allergan"), and Correvio International Sarl, a Swiss corporation with offices at Rue des Alpes 21, Case postale 1674, 1201 Geneva, Switzerland ("Licensee"). Each of Allergan and Licensee is referred to herein individually as a "Party" and collectively as the "Parties." Certain capitalized terms have the meanings provided in Article I below.

Geo Point Resources, Inc. – LICENSE AGREEMENT W - 1/18 ON THE TRANSFER OF a GENERAL, EXCLUSIVE, UNLIMITED AND PERPETUAL LICENSE TO USE THE TECHNOLOGY, KNOW-HOW, DEVELOPMENT AND TECHNICAL KNOWLEDGE for Industrial and Commercial Applications of the Complex TOR Technology and Utility Model Tornado in the Mining Industry, Enrichment of Rocks and Processing of Mineral Raw Materials and Technogenic Accumulations (July 12th, 2018)
Alcobra Ltd. – License Agreement (July 10th, 2018)

This LICENSE AGREEMENT ("Agreement"') is made as of this 28th day of November, 2012 ("Effective Date"), by and between Protiva Biotherapeutics Inc., a British Columbia corporation ("Protiva"), and Marina Biotech, Inc., a Delaware corporation ("Marina"). Protiva and Marina are each referred to individually as a "Party" and together as the "Parties."

Vaccinex, Inc. – LICENSE AGREEMENT Dated as of November 6, 2017 by and Between Vaccinex, Inc. And VX3 (DE) LP (July 9th, 2018)

THIS LICENSE AGREEMENT (this Agreement), dated as November 6, 2017 (the Effective Date), is by and between Vaccinex, Inc., a Delaware corporation having an address at 1895 Mt. Hope Avenue, Rochester, New York, 14620 (Transferor), and VX3 (DE) LP, a Delaware limited partnership having an address at 200 Bay Street, Suite 3800, Royal Bank Plaza, South Tower, Toronto, Ontario, Canada M5J 2Z4 (Transferee). Transferor and Transferee may be referred to each individually as a Party or together as the Parties.

Arlo Technologies, Inc. – FORM OF INTELLECTUAL PROPERTY RIGHTS CROSS-LICENSE AGREEMENT BY AND BETWEEN NETGEAR, INC. AND ARLO TECHNOLOGIES, INC. Dated as of [], 2018 (July 6th, 2018)

This INTELLECTUAL PROPERTY RIGHTS CROSS-LICENSE AGREEMENT (this Agreement), dated as of [], 2018, is by and between NETGEAR, Inc., a Delaware corporation, and Arlo Technologies, Inc., a Delaware corporation.

Athenex, Inc. – LICENSE AGREEMENT by and Between XIANGXUE LIFE SCIENCES LTD. And AXIS THERAPEUTICS LIMITED June 29, 2018 (July 2nd, 2018)

THIS LICENSE AGREEMENT (this Agreement) is made as of June 29, 2018 (the Effective Date), by and between Xiangxue Life Sciences Ltd., a company organized and existing under the laws of the Peoples Republic of China and having its principal office at 2 Jinfengyuan Road, Guangzhou, China (Licensor or XLifeSc) and Axis Therapeutics Limited, a company organized and existing under the laws of Hong Kong and having its principal office at Unit 608-613 IC Development Centre, No 6 Science Park West Avenue, Science Park, Hong Kong (Licensee and together with Licensor, the Parties and each individually, a Party) and, solely for the purposes of SECTION 4.1, Athenex, Inc. (Athenex).

Boston Therapeutics, Inc. – License Agreement (July 2nd, 2018)

THIS LICENSE AGREEMENT ("Agreement") is made and entered into as of this 26th day of June, 2018 (the "Effective Date"), by and between Level Brands, Inc., a North Carolina corporation, its subsidiary Level H & W, LLC a North Carolina limited liability company, together ("Licensor"), and Boston Therapeutics, Inc., a Delaware corporation ("Licensee"). Licensor and Licensee sometimes collectively referred to herein as "Parties" or, individually, as "Party."